1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This Funding Opportunity Announcement (FOA) invites applications for the Alzheimers Disease (AD) and Alzheimers Disease-Related Dementias (ADRD) Real-World Data (RWD) Platform initiative. This Platform aims to transform the AD/ADRD research enterprise by serving as a central hub of research access that aims to: 1) improve applicability and generalizability of findings through larger datasets that include more diverse populations; 2) capture more complete information through linking a variety of data sources; 3) increase the speed at which scientific questions can be answered; and 4) improve researchers ability to answer questions that cannot be feasibly or readily answered via clinical trial.
Funding Opportunity Number: RFA-AG-24-009. Assistance Listing: 93.853,93.866. Funding Instrument: CA. Category: HL. Award Amount: Up to $52M per award.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: Eligible applicants: State governments; County governments; City or township governments; Special district governments; Independent school districts; Public and State controlled institutions of higher education; Native American tribal governments (Federally recognized); Public housing authorities / Indian housing authorities; Native American tribal organizations (other than Federally recognized); Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education; Private institutions of higher education; For-profit organizations other than small businesses; Small businesses; Others (see text field entitled Additional Information on Eligibility for clarification). Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed. Confirm the full requirements in the official notice before applying.
The current listing shows up to $52M per award. Verify award ceilings, matching requirements, and allowable costs in the official notice.
The published deadline was July 31, 2023, which has passed. Check the official notice for any future application windows before investing time in a proposal.
Yes — Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) Real-World Data Platform (U54 Clinical Trial Optional) is offered by National Institutes of Health and this listing comes from Grants.gov, an official U.S. federal source. Federal applications generally require registrations (for example SAM.gov or an agency submission portal), so allow extra lead time.
This opportunity targets applicants in Alaska and Hawaii. Check the official notice for exact location requirements.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
Small Business Technology Transfer (STTR) Program is sponsored by National Institute on Aging (NIA), National Institutes of Health (NIH). The NIA STTR program encourages small businesses to collaborate formally with research institutions to develop and commercialize innovative treatments or technologies to help people enjoy healthier lives as they age, including solutions for Alzheimer's disease and related dementias. This program supports feasibility studies to later stage research and development (R&D) needed to develop a commercial product.
NIA Small Business Programs (SBIR & STTR) is sponsored by National Institute on Aging - NIH. The NIA Small Business Programs manage the largest source of early-stage funding for aging-related research and development (R&D). They provide grants to small businesses through the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs to develop innovative technologies that enhance the health and well-being of older adults, including digital health and sensing technologies that address factors impacting the aging population, Alzheimer's disease, and related dementias. This includes technologies that promote aging in place and reduce caregiving burden.
PA-27-037 consolidates the Predoctoral to Postdoctoral Transition Award into a single parent announcement across 20 NIH components, with the next deadline December 8, 2026. The eligibility gate is not the science — it is a mandatory change of institution and mentor between the F99 and K00 phases.
Read articleA draft executive order would have put OMB Director Russell Vought on a commission with final say over NIH awards after peer review. Sen. Collins killed it by pointing at a provision Congress already passed. Here is what the episode teaches applicants about the December 11 cliff.
Read articlePA-27-034, PA-27-035 and PA-27-036 replace the institute-specific R25 announcements that research education programs have been built around for a decade. NCI, NIDA and NIGMS have already expired theirs early. Here is what the consolidation actually changes: an 8% indirect cost ceiling, a US-citizens-and-permanent-residents participant rule, a cooperative agreement variant that only exists on one of the three, and no clinical-trial-allowed companion anywhere.
Read article